ხუთშაბათი, აპრილი 16, 2026
- Advertisement -
Google search engine
Global Ingredient Risk Index Botanical

Ginger Root Extract

Zingiber officinale

Also known as: Ginger extract, Zingiber officinale root extract, Gingerol extract

LOW RISK 2.0/10 How?

This ingredient is classified as unclassified risk (GIRI score: 2.0/10).

02

Safety Profile

Information not yet available for this ingredient profile.

═══════════════════════════════════════════════════════════════════════ -->
03

Interactions

Information not yet available for this ingredient profile.

═══════════════════════════════════════════════════════════════════════ -->
04

Evidence and Scientific Findings

Overview

Ingredient Overview

Ginger root extract is used for nausea, GI discomfort, and anti-inflammatory effects. It is safe at culinary and standard supplemental doses. High doses may cause heartburn. It has mild antiplatelet effects; caution is warranted with anticoagulants and before surgery. May lower blood glucose, requiring monitoring in diabetic patients.

Classification

Biological and Chemical Classification

Scientific Name
Zingiber officinale
Mechanism

Mechanism of Action

Information not yet available for this ingredient profile.

Clinical Evidence

Clinical Evidence of Effectiveness

Information not yet available for this ingredient profile.

Pharmacokinetics

Pharmacokinetics

Information not yet available for this ingredient profile.

Dosage

Recommended Dosage

Information not yet available for this ingredient profile.

═══════════════════════════════════════════════════════════════════════ -->
05

SETI — Scientific Evidence Transparency Index

SETI Score 50/100
Risk Level High risk
Scientific Confidence Low
Evidence Strength Limited
Key Benefit Botanical
Evidence Reviewed 10 PubMed studies
Scientific Confidence Low
Based on study quality, consistency, and recency

Executive Summary — Ingredient Assessment

SETI Score 50/100
Risk Level High risk
Evidence Strength Limited
Main Benefit Botanical
Ingredient Ginger Root Extract
Scientific name Zingiber officinale
Scientific Evidence Overview
  • 10 studies reviewed
  • 0 high-quality studies (meta-analysis or RCT)
  • Main clinical benefit observed: Botanical
  • Evidence consistency: High consistency across studies (100%)
Safety Signals
  • No significant safety signals identified in the reviewed literature.
Evidence Strength Limited
Final Scientific Assessment

The available scientific evidence for Ginger Root Extract indicates notable safety signals that warrant caution. Use should be considered carefully and monitored, particularly in sensitive populations or alongside other medications.

Ingredient Ginger Root Extract
Evidence reviewed 10 peer-reviewed studies (last 10 years)
Scientific name Zingiber officinale
50 /100

Total SETI Score

High risk
Evidence quality 10/40
Evidence consistency 20/20
Safety signals 0/20
Study recency 10/10
Evidence transparency 10/10

Evidence Summary

  • 10 studies reviewed
  • 0 high-quality studies (meta-analysis or systematic review)
  • 0 studies identified benefits or no safety concern (GREEN)
  • 10 studies reported limited or advisory safety evidence (YELLOW)

Evidence Policy

Only peer-reviewed scientific literature indexed in PubMed or comparable databases is included in this evaluation. Commercial websites, blogs, and marketing materials are excluded. All references include direct traceable links to source documents.

Last updated: 26 მარ 2026, 14:03

Evidence Distribution

10 Other / unclassified
  1. Observational / other LOW evidence YELLOW
    Phyto mediated synthesis of copper oxide nanoparticles with Zingiber officinale: comprehensive bioactivity assessment against bacterial pathogens, cancer, and viruses. ↗
    PMID 41864923 ↗
    Journal BMC Biotechnol
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41864923/
    Soliman MKY et al.. Phyto mediated synthesis of copper oxide nanoparticles with Zingiber officinale: comprehensive bioactivity assessment against bacterial pathogens, cancer, and viruses.. BMC Biotechnol. 2026. PMID:41864923.
  2. Observational / other LOW evidence YELLOW
    Enhanced wound healing in rat cheeks treated with lavender and ginger oils: A histological study. ↗
    PMID 41859131 ↗
    Journal J Taibah Univ Med Sci
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41859131/
    Kadim EF et al.. Enhanced wound healing in rat cheeks treated with lavender and ginger oils: A histological study.. J Taibah Univ Med Sci. 2026. PMID:41859131.
  3. Observational / other LOW evidence YELLOW
    Temporal volatile profile and yield dynamic of ginger in relation to climatic variation during harvest. ↗
    PMID 41850099 ↗
    Journal Food Chem
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41850099/
    Tan Q et al.. Temporal volatile profile and yield dynamic of ginger in relation to climatic variation during harvest.. Food Chem. 2026. PMID:41850099.
  4. Observational / other LOW evidence YELLOW
    A systematic review of ethnobotanical study in Indonesia: diversity and cultural patterns of medicinal plant use. ↗
    PMID 41840403 ↗
    Journal J Ethnobiol Ethnomed
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41840403/
    Febriyanti RM et al.. A systematic review of ethnobotanical study in Indonesia: diversity and cultural patterns of medicinal plant use.. J Ethnobiol Ethnomed. 2026. PMID:41840403.
  5. Observational / other LOW evidence YELLOW
    Chemometric classification of red ginger (Zingiber officinale var. Rubrum) oleoresin from different regions using Fourier-transform infrared-ATR spectroscopy. ↗
    PMID 41836778 ↗
    Journal J Adv Pharm Technol Res
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41836778/
    Nurmansyah A et al.. Chemometric classification of red ginger (Zingiber officinale var. Rubrum) oleoresin from different regions using Fourier-transform infrared-ATR spectroscopy.. J Adv Pharm Technol Res. 2026. PMID:41836778.
  6. Observational / other LOW evidence YELLOW
    Magnesium Oxide Nanoparticles Loaded with 6-Gingerol: A Bioinspired Approach to Anticancer, Anti-Inflammatory, and Antioxidant Therapy. ↗
    PMID 41836722 ↗
    Journal Int J Nanomedicine
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41836722/
    Kamaraj C et al.. Magnesium Oxide Nanoparticles Loaded with 6-Gingerol: A Bioinspired Approach to Anticancer, Anti-Inflammatory, and Antioxidant Therapy.. Int J Nanomedicine. 2026. PMID:41836722.
  7. Observational / other LOW evidence YELLOW
    Enhanced transdermal delivery of [6]-Gingerol via Co-Administration of Acmella oleracea and Zingiber officinale lipophilic extracts. ↗
    PMID 41819387 ↗
    Journal Int J Pharm
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41819387/
    Magnano GC et al.. Enhanced transdermal delivery of [6]-Gingerol via Co-Administration of Acmella oleracea and Zingiber officinale lipophilic extracts.. Int J Pharm. 2026. PMID:41819387.
  8. Observational / other LOW evidence YELLOW
    Phytoextracts Used in the Treatment of Cryptosporidiosis and Giardiasis: Current State. ↗
    PMID 41817887 ↗
    Journal Acta Parasitol
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41817887/
    Namboodiri AP et al.. Phytoextracts Used in the Treatment of Cryptosporidiosis and Giardiasis: Current State.. Acta Parasitol. 2026. PMID:41817887.
  9. Observational / other LOW evidence YELLOW
    Zingerone attenuates steatosis via downregulation of AQP9 in hepatocytes. ↗
    PMID 41814034 ↗
    Journal Naunyn Schmiedebergs Arch Pharmacol
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41814034/
    Mate PS et al.. Zingerone attenuates steatosis via downregulation of AQP9 in hepatocytes.. Naunyn Schmiedebergs Arch Pharmacol. 2026. PMID:41814034.
  10. Observational / other LOW evidence YELLOW
    Ginger as a nutraceutical shield: Counteracting acrylamide-induced liver injury. ↗
    PMID 41809463 ↗
    Journal World J Hepatol
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41809463/
    Massimi A et al.. Ginger as a nutraceutical shield: Counteracting acrylamide-induced liver injury.. World J Hepatol. 2026. PMID:41809463.
═══════════════════════════════════════════════════════════════════════ -->
06

Score Transparency

Q × L × D × S × 10 = 2.0 / 10

The GIRI Score is the product of four independently computed evidence components, each normalised to 0–1, then scaled to 0–10. Every component is derived exclusively from peer-reviewed references and regulatory data — no editorial judgement is applied.

Q
Evidence Quantity 0 / 10
0%

0 of 10 approved references (score saturates at 10). More peer-reviewed studies = stronger evidence base.

Method: Q = number of approved references ÷ 10 (capped at 1.0)

L
Evidence Quality 5 / 10
50%

Limited — mostly case reports or animal studies

Method: L = mean study-level weight across approved references. Level 1 (meta-analysis / systematic review) = 1.0; Level 2 (RCT) = 0.8; Level 3 (cohort/case-control) = 0.6; Level 4 (case report) = 0.4; Level 5 (animal / in-vitro) = 0.2.

D
Evidence Direction 5 / 10
Benefit
Risk
50%

Mixed or neutral — roughly equal benefit and risk signals

Method: D = (sum of risk-scored references − sum of benefit-scored references) ÷ total evidence score, then scaled from [−1, 1] to [0, 1]. 0.0 = pure benefit; 0.5 = neutral; 1.0 = pure risk.

S
Safety Signals 5 / 10
50%

One or more monitoring-level safety signals active

Method: S = 0.5 (neutral baseline) + sum of active signal severity deltas ÷ 10. Severity deltas: Critical = +2.0, High = +1.5, Moderate = +1.0, Low = +0.5. Capped at 1.0.

0Q × 5L × 5D × 5S = 2.0 / 10

Final GIRI Score for Ginger Root Extract. Risk level thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.

Full methodology & data sources

The GIRI Score is computed entirely from structured data — no editorial scoring or subjective weighting is applied at any step.

  • References: Only approved references are counted. Each reference is assigned an evidence level (L1–L5) and a direction (risk / neutral / benefit) by the reference manager or AI classifier.
  • Safety Signals: Sourced from regulatory agencies (FDA, EMA, Health Canada, TGA, and others) and pharmacovigilance databases. Only active signals count toward the score.
  • Formula version: GIRI Score v3.7.0 — Q × L × D × S × 10.
  • Limitations: The score reflects published evidence and recorded signals as of the last update date. It is not a clinical risk assessment and should not replace advice from a qualified healthcare professional.
07

Risk Level Classification

LOW RISK 2.0/10

Based on available regulatory signals and scientific evidence, this ingredient presents a low safety concern under normal conditions of use.

LOW
0–3.0
MODERATE
3.0–5.5
HIGH
5.5–7.5
CRITICAL
7.5–10
2.0

The score pin shows exactly where this ingredient falls on the fixed risk scale.

What drove the Low classification for Ginger Root Extract

GIRI Score 2.0 / 10

A score of 2.0 places this ingredient in the Low band. Thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.

Evidence Quantity (Q) 0 / 10 refs

0 approved references.

Evidence Quality (L) 50%

Limited — mostly case reports or animal studies (Level 4–5).

Evidence Direction (D) 50% toward risk

Neutral or mixed — benefit and risk signals roughly balanced.

Safety Signals (S) 0 active signals

No active signals — S component is at neutral baseline (0.5), contributing no extra risk weight.

Regulatory Status No restrictions found

No major regulatory restrictions or advisories recorded across monitored jurisdictions (FDA, EMA, Health Canada, TGA, and others).

How are the Low / Moderate / High / Critical thresholds defined?

The four risk levels are fixed score bands. A score is assigned to exactly one level based on where it falls:

LevelScoreMeaning
LOW0.0 – 2.9Sparse or predominantly beneficial evidence. No active safety alerts.
MODERATE3.0 – 5.4Mixed signals — some risk alongside benefit. Caution at high doses or in sensitive groups.
HIGH5.5 – 7.4Multiple studies or regulatory alerts documenting adverse effects. Professional oversight recommended.
CRITICAL7.5 – 10Regulatory restrictions in one or more major jurisdictions. Serious documented harm. Avoid without specialist supervision.

Thresholds are fixed constants (GIRI_Score_Utils::LEVEL_THRESHOLDS). They do not change per ingredient and are never subject to editorial adjustment.

← Back to Ingredient Database

ბოლო სიახლეები

პოპულარული ამბები

კატეგორიები

ჩვენ შესახებ

info@accreditation.ge
ჩვენს შესახებ / რეკლამა / კონტაქტი

გამოგვყევი სოციალურ ქსელებში

© SheniEkimi.ge